]> 2026-10-17T04:59:55+00:00 Trials (Helsinki University Hospital Comprehensive Cancer Center) 0 en A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma Low-dose Computer Tomography in Follow-up of Soft Tissue Sarcomas Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Radiotherapy Delivery in Deep Inspiration for Pediatric Patients Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma 2025-12-14T14:14:53Z 2461024.093669 Trials (Helsinki University Hospital Comprehensive Cancer Center) Helsinki University Hospital Comprehensive Cancer Center 0 en Helsinki University Hospital Comprehensive Cancer Center HasClinicalTrial 102 en HasClinicalTrial